Company intelligence / Profile preview

Palisade Concentrated Equity

Carlsbad, California, United States

Ownership: Public · PALI
Employees: ~8
Development stage: Other

Overview

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing oral PDE4 inhibitor prodrugs for the treatment of autoimmune, inflammatory, and fibrotic diseases. The company's lead candidate, PALI-2108, is a locally-bioactivated PDE4 inhibitor designed to target the colon and ileum, providing potent anti-inflammatory effects while minimizing systemic exposure and associated side effects. Palisade Bio aims to transform the treatment landscape for inflammatory bowel diseases (IBD) through its precision pharmacology platform and targeted delivery technology. The company is currently advancing its lead program into Phase 2 clinical trials for Ulcerative Colitis.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Giiant PharmaNewsoara Biopharma

Beyond the preview

Go deeper on Palisade Concentrated Equity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Palisade Concentrated Equity.

Explore the full profile